Denosumab for Treatment of Hypercalcemia of Malignancy | Zendy

Mimi I. Hu | Zendy; Ilya Glezerman | Zendy; Sophie Leboulleux | Zendy; Karl Insogna | Zendy; Rasim Gucalp | Zendy; Waldemar Misiorowski | Zendy; Bennett W. Yu | Zendy; Paul Zorsky | Zendy; Diégo Tosi | Zendy; Alberto Bessudo | Zendy; Arnaud Jaccard | Zendy; Giuseppe Tonini | Zendy; Wendy Ying | Zendy; Ada Braun | Zendy; Rajul K. Jain | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Denosumab for Treatment of Hypercalcemia of Malignancy

Author(s) -

Mimi I. Hu,

Ilya Glezerman,

Sophie Leboulleux,

Karl Insogna,

Rasim Gucalp,

Waldemar Misiorowski,

Bennett W. Yu,

Paul Zorsky,

Diégo Tosi,

Alberto Bessudo,

Arnaud Jaccard,

Giuseppe Tonini,

Wendy Ying,

Ada Braun,

Rajul K. Jain

Publication year - 2014

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2014-1001

Subject(s) - denosumab , malignancy , medicine , context (archaeology) , osteoclast , bisphosphonate , bone resorption , oncology , cancer , osteoporosis , paleontology , receptor , biology

Hypercalcemia of malignancy (HCM) in patients with advanced cancer is often caused by excessive osteoclast-mediated bone resorption. Patients may not respond to or may relapse after iv bisphosphonate therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research